Contra The companys headline financials offer little meat to investors, as it reported a $140 million loss on $804 million of revenue in 2023
Li B, Wei S, Yang L, Peng X, Ma Y, Wu B, et al
Support cardiovascular health (due to its role in heart muscle energy)
Although Semaglutide GLP-1 is effective, it may cause mild to moderate side effects, primarily gastrointestinal symptoms
Fen-phen crashed and burned after it was found to cause serious cardiovascular problems
However, coverage for weight loss drugs covered by UnitedHealthcare in 2025 might differ, so always check your specific plan details